Physician profile
Gary E Borodic
NPI 1568456291
$5,399.84
in general payments reported to CMS, 2019-2025
23 companies · $921 in 2025
The $921 reported for 2025 was more than what 75% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $498 · 2020: $273 · 2021: $1,097 · 2022: $537 · 2023: $1,045 · 2024: $1,029 · 2025: $921.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,961 · Education: $34.12.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,960.88 |
| Education | $34.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $1,660.90 | 2023-2025 | Acthar |
| Abbvie INC. | $1,553.57 | 2021-2025 | Ubrelvy, Qulipta, Botox |
| Amgen INC. | $463.61 | 2020-2025 | Uplizna, Tepezza, Aimovig |
| Biohaven Pharmaceuticals, INC. | $374.50 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $357.91 | 2019 | |
| Horizon Therapeutics Plc | $193.29 | 2020-2022 | |
| Pfizer INC. | $190.17 | 2023-2025 | |
| Sun Pharmaceutical Industries INC. | $112.09 | 2019-2021 | |
| Allergan, INC. | $91.04 | 2020-2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $69.33 | 2022 | |
| Lundbeck LLC | $50.02 | 2022-2025 | Vyepti |
| Tarsus Pharmaceuticals, INC. | $39.04 | 2024 | Xdemvy |
| Aerie Pharmaceuticals, INC. | $37.11 | 2019 | |
| Alexion Pharmaceuticals, INC. | $34.12 | 2023 | Ultomiris |
| Oyster Point Pharma, INC. | $26.64 | 2022 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $23.99 | 2019 | |
| Alcon Vision LLC | $20.95 | 2019 | |
| Thea Pharma INC. | $20.60 | 2025 | Iyuzeh |
| Apellis Pharmaceuticals, INC. | $20.43 | 2024 | Syfovre |
| Glaukos Corporation | $17.84 | 2019 | |
| Ani Pharmaceuticals, INC. | $16.43 | 2023 | Purified Cortrophin Gel |
| Eyevance Pharmaceuticals LLC | $15.05 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $11.21 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gary Borodic listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.